DermTech (NASDAQ:DMTK – Get Free Report)‘s stock had its “equal weight” rating reaffirmed by equities researchers at Stephens in a research note issued on Friday, Benzinga reports. They presently have a $1.50 price objective on the stock. Stephens’ price target points to a potential upside of 132.92% from the company’s previous close. Separately, BTIG Research […]

Related Keywords

Switzerland , United States , Swiss , , Dermtech Inc , Swiss National Bank , Dermtech Company Profile , Centaurus Financial Inc , Charles Schwab Investment Management Inc , Jpmorgan Chase Co , Get Free Report , Schwab Investment Management , National Bank , Dermtech Melanoma Test , Dermtech Daily , Dermtech , Nasdaq Dmtk , Dmtk , Medical , Reiterated Rating , Stephens ,